News

Without savings from the 340B Drug Pricing Program as a lifeline, hospitals face service reductions or even closure.

The FDA has approved the sunscreen ingredient bemotrizinol, which blocks both UVA and UVB rays.

Prior authorization and high out-of-pocket costs impact blood cancer patients' access to oral cancer drugs, according to a poster at the 2026 ASCO Meeting.

The FDA has set a target action date of July 29, 2026, for Lytenava to treat patients with wet age-related macular degeneration. Outlook Therapeutics had successfully appealed a complete response letter issued in December 2025.

Things got messy fast after ADA security pulled researchers out of its 2026 conference for passing around an anti-NIH-cuts editorial — cue a walkout, a couple of high-profile resignations and a CEO apology video to try to smooth things over.

The Veterans Affair’s Whole Health approach includes mindfulness, acupuncture, nutritional counseling, and a free app to help patients manage chronic pain.

Researchers analyzing seven oncology therapies found most U.S. commercial plans treat subcutaneous and IV formulations equally, but five payers enforced IV-preferred policies, according to a poster released at the 2026 ASCO meeting.

A fully remote genetic screening program and a multicenter quality improvement initiative both advanced early type 1 diabetes detection.

A University of Pittsburgh study found that one RSV shot during pregnancy cut the odds of a newborn landing in the hospital by nearly 70%.

Demand for behavioral healthcare has surged, increasing costs for health plans and employers as millions of Americans deal with mental illness, substance use disorders and access challenges.

Larotrectinib is a kinase inhibitor used to treat adult and pediatric patients with solid tumors that are positive for NTRK gene fusions. Vitraki was the first approved tumor-agnostic therapy.

Two food access interventions, one of which combined grocery delivery with community health worker coaching, showed significant improvements in diabetes control, food insecurity and overall health outcomes across both youth and adult populations.

Until trials confirm that treatment guided by circulating tumor DNA treatment improves survival rather than simply predicting it, the tests remain prognostic tools in search of proven clinical utility.

Artificial intelligence models matched mid-career dermatologists but trailed seasoned experts in diagnosing skin lesions across real-world cases.

Lung cancer has seen major advances in targeted therapies and immunotherapy but fewer than half of older adults with metastatic non-small cell lung cancer ever receive systemic treatment.

The FDA has approved a new maintenance dosing schedule for Ebglyss that reduces injections to as few as six per year for patients with moderate to severe atopic dermatitis.

An electronic health record–based model could help health systems target diabetes prevention to the high-risk patients most likely to benefit.

The REIMAGINE 1, 2 and 3 trials each met their primary HbA1c end point and confirmatory secondary end points for body weight reduction.

An individualized mRNA neoantigen vaccine added to pembrolizumab reduced the risk of recurrence by 49% and distant metastasis by 59% in resected high-risk melanoma, with benefits holding through five years of follow-up in a phase 2b trial.

Nearly half of payers not covering GLP-1s for obesity say no price would change their minds on coverage, citing high costs, poor adherence, and weight regain concerns, finds a new survey by PSG.

Cambridge researchers have completed the first human trial of pEVAC-PS, an AI-designed vaccine intended to protect against the entire family of Sarbeco viruses, finding it safe and well tolerated across all dose levels, with modest immune responses that warrant further investigation in a phase 2 trial.

A decision on Alvotech’s BLA for AVT16 could come as soon as the first quarter of 2027, but Entyvio’s patent doesn’t expire until 2032.

The experimental glucagon/GLP-1 dual agonist showed targeted reductions in metabolically harmful fat alongside meaningful weight loss in two distinct patient populations.

As value-based care continues to evolve, models that embed physician input into decision-making, align incentives and maintain transparency are more likely to sustain improvement.

Pfizer plans 10 phase 3 trials of berobenatide for chronic weight management and obesity-related comorbidities.

The first triple hormone receptor agonist to reach phase 3 development demonstrated results that researchers say could reshape how clinicians approach obesity and type 2 diabetes treatment.

Results presented at ADA 2026 mark the first Level A evidence supporting CGM use in this population.

Joanne Mortimer, M.D., of City of Hope breaks down new data linking GLP-1 receptor agonist use to a reduction in mortality across multiple tumor types.